Vimalkumar Patel, MD
Pulmonary Disease · Topeka, KSNPI 1750776704
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,549 of the $5,428 with a category attached, or 65.4%. 21 manufacturers reported payments, led by Covidien LP at 43.4% of the total.
Across 133 payments — averaging $40.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$2K
- AstraZeneca$730
- Sanofi$301
- Grifols USA, LLC$263
- GSK$218
- Regeneron Healthcare Solutions, Inc.$213
- plus $1K from 15 others
What the payments were for
- Travel & lodging$1,87935%
- Food & beverage$3,54965%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covidien LP | 10 | $2,357 |
| AstraZeneca | 32 | $730 |
| Sanofi | 11 | $301 |
| Grifols USA, LLC | 10 | $263 |
| GSK | 11 | $218 |
| Regeneron Healthcare Solutions, Inc. | 8 | $213 |
| Jazz Pharmaceuticals Inc. | 7 | $195 |
| Amgen | 8 | $178 |
| Insmed, Inc. | 8 | $141 |
| Axsome Therapeutics, Inc. | 6 | $140 |
| Boehringer Ingelheim | 4 | $125 |
| Pharming Healthcare, Inc. | 1 | $108 |
| Actelion Pharmaceuticals US, Inc. | 3 | $106 |
| Harmony Biosciences LLC | 3 | $85 |
| AbbVie | 4 | $78 |
| Abiomed | 1 | $47 |
| Lilly USA, LLC | 2 | $42 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $26 |
| Philips North America LLC | 1 | $22 |
| Gilead | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- superDimension$1,955
- RUCONEST$108
How this compares
$5,428 in reported general payments places this provider in the 65th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $70,469 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 62 | $26,922 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $18,723 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $14,636 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $11,631 |
| Spiriva RespimatTiotropium Bromide | 15 | $7,809 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 117 | $3,891 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,363 |
| Ventolin HfaAlbuterol Sulfate | 31 | $2,890 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $2,775 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $2,039 |
| Roflumilast | 13 | $941 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 12 | $555 |
| Bupropion XlBupropion Hcl | 27 | $505 |
| Azithromycin | 18 | $364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $218 | $109,022171 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $125 | $22,44534 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $730 | $22,08739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Topeka
- Hassan TahaTopeka$7K
- Miguel Tsukayama OdaTopeka$6K
- Abhishek ChakrabortiTopeka$4K
- Amanda GudgellTopeka$856
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Abdel-Ghanie Abu-SamraWichita$60K
- Robert SourkHutchinson$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.